This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Fumarate hydratase (FH); heme oxygenase decycling 1 (HMOX1; HO-1)	<p>Cell culture studies suggest inhibiting HMOX1 could help treat hereditary leiomyomatosis and renal cell cancer (HLRCC), which is caused by mutations in the <i>FH</i> gene. In human HLRCC cells, an HMOX1 inhibitor decreased proliferation compared with vehicle. Next steps include evaluating HMOX1 inhibitors in mouse models of <i>FH</i> mutant cancers.</p> <p>Osta Biotechnologies Inc.'s HMOX1 inhibitor, OB-24, is in preclinical development for prostate cancer.</p> <p>SymBio Pharmaceuticals Ltd.'s HMOX1 inhibitor, SyB-0702, is in preclinical development for solid tumors.</p> <p>SciBX 4(33); doi:10.1038/scibx.2011.930 Published online Aug. 25, 2011</p>	Unpatented; licensing status not applicable	<p>Frezza, C. <i>et al. Nature</i>; published online Aug. 17, 2011; doi:10.1038/nature10363</p> <p>Contact: Eyal Gottlieb, Beatson Institute for Cancer Research, Glasgow, U.K. e-mail: e.gottlieb@beatson.gla.ac.uk</p>